drug
CSB-001
Phase 2updated 3mo agoby Claris Biotherapeutics Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying CSB-001
- phase1Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
- phase1Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
- phase2Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
News(2)
- An eye drug biotech banks $118M and stocks its executive suiteClaris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.biopharma_dive · 18d ago
- ‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugA new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.fiercebiotech · 18d ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that